We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01739673
Recruitment Status : Completed
First Posted : December 3, 2012
Last Update Posted : February 3, 2017
Information provided by (Responsible Party):

Brief Summary:
This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Condition or disease Intervention/treatment
Infectious Keratitis Other: Ultraviolet-A and riboflavin

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis
Study Start Date : August 2011
Primary Completion Date : July 2014
Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Riboflavin
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Ultraviolet-A and riboflavin Other: Ultraviolet-A and riboflavin

Primary Outcome Measures :
  1. Resolution of Signs and Symptoms of Infectious Keratitis [ Time Frame: Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must be 18 years of age or older.
  2. Ability to provide written informed consent.
  3. Likely to complete all study visits.
  4. Subjects must have one eye that with a diagnosis of infectious keratitis.

Exclusion Criteria:

  1. A corneal perforation.
  2. Descemetocele.
  3. Pregnancy or breastfeeding.
  4. Active Herpes corneal disease.
  5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01739673

United States, Arizona
Schwartz Laser Eye Center
Scottsdale, Arizona, United States
United States, California
Davidorf Eye Group
West Hills, California, United States
United States, Colorado
Corneal Consultants of Colorado, PC
Littleton, Colorado, United States
United States, Florida
Center for Excellence in Eye Care
Miami, Florida, United States
United States, Minnesota
Minnesota Eye Consultants
Minneapolis, Minnesota, United States
United States, Missouri
Ophthalmology Associates
St. Louis, Missouri, United States
Sponsors and Collaborators
Study Director: William Trattler, MD Center For Excellence In Eye Care

Responsible Party: Cxlusa
ClinicalTrials.gov Identifier: NCT01739673     History of Changes
Other Study ID Numbers: iCXL
First Posted: December 3, 2012    Key Record Dates
Last Update Posted: February 3, 2017
Last Verified: August 2015

Keywords provided by Cxlusa:
Infectious Keratitis

Additional relevant MeSH terms:
Communicable Diseases
Corneal Diseases
Eye Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents